Publication, Part of Case-mix Adjusted Percentage of Cancers Diagnosed at Stages 1 and 2 in England
Case-mix Adjusted Percentage of Cancers Diagnosed at Stages 1 and 2 by ICB in England, 2022
Official statistics
Summary
This publication presents the 1- and 3- year unadjusted and case-mix adjusted ‘percentage of all cancers diagnosed at stages 1 and 2’ indicator nationally and at Integrated Care Board (ICB) level. The most recently available results are for cancers diagnosed in 2022 with data available from 2013. The unadjusted percentage of cancers diagnosed at each stage is provided by cancer group and deprivation quintile. It also presents the 1-year rolling unadjusted ‘percentage of all cancers diagnosed at stages 1 and 2’ indicator (known as 75% ambition indicator) nationally and at Cancer Alliance level.
Highlights
New in this publication:
- Cancer groups: To better reflect the variety of cancers that patients are diagnosed and treated with, this publication introduces new cancer groups. The different groups introduced have been consulted on with patient representatives, charities, and clinicians. The groups are defined using either ICD-O-2, ICD-O-3, or ICD-10 dependent on the cancer group. Please refer to 'Appendix A - Cancer group definitions' for the cancer group lookup tables. This means that the results reported in this publication are not comparable with previous iterations of this publication. Within the current publication results are restated back to 2013, therefore previous iterations of this publication have been superseded.
- Geographies: Integrated Care Systems (ICS) were legally established on 1 July 2022, covering all of England. Each ICS has an Integrated care board (ICB) which are NHS organisations responsible for planning health services for their local population. To help ICBs monitor cancer activity and groups facing inequalities, this publication will now present the Case-mix adjusted percentage of cancers diagnosed at stages 1 and 2 indicator at ICB level.
More information regarding the changes to this publication and full methodology can be found in the Case-mix Adjusted Percentage of Cancers Diagnosed at Stages 1 and 2 in England Methodology document, which can be accessed in the Related Links section below.
NDRS User Research Opportunities
We are always looking for opportunities to embed user led approaches in our work and to continually assess and improve the service based on user feedback. Find out more about the NDRS User-Centred Design (UCD) principles on our website.
If you would be interested in supporting us by providing feedback on our outputs, please complete the online registration form below. You can decide which projects you would like to engage with, and you can opt-out at any time.
Registration form: NDRS user research register
Key Facts
The unadjusted percentage of cancers diagnosed at stages 1 and 2 increased in 2022 compared to 2021
55% of cancers with a valid stage were diagnosed at stages 1 and 2 in 2022, which is a higher proportion than every year between 2013 and 2021 where 54% were diagnosed at stages 1 and 2, with the exception of 2020 where the proportion was 52%
Part of the variation in the percentage of cancers diagnosed at stages 1 and 2 between ICBs is associated with population characteristics
Case-mix adjusted percentages across the 42 ICBs range from 53% to 60% in 2020 to 2022, which is smaller than the unadjusted range (51% to 60%)
The unadjusted percentage of cancers diagnosed at stages 1 and 2 varied by cancer group
This ranged from 19% (Oesophagus including cardia and gastroesophageal junction) to 90% (Testes)
The unadjusted percentage of cancers diagnosed at stages 1 and 2 is lower in areas with higher deprivation
The unadjusted percentage of cancers diagnosed at stages 1 and 2 in the 20% most deprived areas of England is 8 percentage points lower than for those in the 20% least deprived areas (51% versus 59%)
The unadjusted percentage of cancers diagnosed at stages 1 and 2 is higher in areas with higher deprivation for lung and ovarian cancer
The unadjusted percentage of cancers diagnosed at stages 1 and 2 in the 20% most deprived areas of England is 2 percentage points higher for lung cancer and 10 percentage points higher for ovarian cancer than for those in the 20% least deprived areas (Lung: 35% versus 32%, Ovary: 44% versus 34%).
Acknowledgements
This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data are collated, maintained and quality assured by the National Disease Registration Service, which is part of NHS England.
Resources
Last edited: 18 September 2025 12:23 pm